Advertisement
U.S. Markets closed

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.8500-0.3300 (-6.37%)
At close: 04:00PM EDT
4.9200 +0.07 (+1.44%)
After hours: 06:20PM EDT

XORTX Therapeutics Inc.

3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
403 455 7727
https://www.xortx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. Allen Warren Davidoff Ph.D.Founder, CEO, President & Director361.96kN/A1960
Mr. James Neville Fairbairn C.A., C.P.A., ICD.DInterim Chief Financial Officer43.18kN/A1963
Dr. Stephen Haworth M.D., MRCPChief Medical Officer230.61kN/A1950
Dr. Stacy Evans M.B.A., M.D.Chief Business Officer85.36kN/A1974
Nick RigopoulosDirector of CommunicationsN/AN/AN/A
Dr. David Sans M.B.A., Ph.D.Director of Corporate DevelopmentN/AN/A1970
Dr. David MacDonald Ph.D.Consultant of Clinical OperationsN/AN/A1964
Ms. Charlotte MayCorporate SecretaryN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.

Corporate Governance

XORTX Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.